<DOC>
	<DOCNO>NCT02773524</DOCNO>
	<brief_summary>Advanced Gastro-oesophageal Carcinoma ( AGOC ) poor prognosis , establish standard treatment follow failure first second line chemotherapy . Regorafenib ( BAY 73-4506 ) investigational oral multi-targeted tyrosine kinase inhibitor ( TKI ) target angiogenic ( VEGF , TIE-2 ) , stromal ( PDGF-β ) , oncogenic ( RAF , RET KIT ) receptor tyrosine kinase , show activity solid tumour . Regorafenib show prolong PFS across regions/subgroups INTEGRATE I The general aim study determine regorafenib improve overall survival refractory AGOC .</brief_summary>
	<brief_title>A Study Regorafenib Refractory Advanced Gastro-Oesophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>1 . Adults ( 18 year ) metastatic locally recurrent gastrooesophageal cancer : 1. arisen primary gastrooesophageal site ( oesophagogastric junction ( GOJ ) stomach ) ; 2. adenocarcinoma undifferentiated carcinoma histology , 3. evaluable accord Response Evaluation Criteria Solid Tumours ( RECIST Version 1.1 ) compute tomography ( CT ) scan perform within 21 day prior randomisation . A lesion previously irradiate area eligible consider measurable disease long objective evidence progression lesion prior study enrolment ; 4. fail intolerant 2 line prior anticancer therapy recurrent/metastatic disease must include least one platinum agent one fluoropyrimidine analogue . Note : Neoadjuvant adjuvant chemotherapy chemoradiotherapy consider first line treatment people relapse progress within 6 month complete treatment ; Radiosensitising chemotherapy give solely purpose concurrent palliative radiation consider line treatment . Ramucirumab monotherapy , immunotherapy checkpoint inhibitor , consider line treatment . 2 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 ( Appendix 1 ) . 3 . Ability swallow oral medication . 4 . Adequate bone marrow function ( Platelets ≥100x109/L ; Absolute Neutrophil Count ( ANC ) ≥1.5x109/L Haemoglobin ≥ 9.0g/dL ) . 5 . Adequate renal function ( Creatinine clearance &gt; 50 ml/min ) base either CockcroftGault formula ( Appendix 2 ) , 24hour urine Glomerular Filtration Rate ( GFR ) scan ; serum creatinine ≤1.5 x Upper Limit Normal ( ULN ) . 6 . Adequate liver function ( Serum total bilirubin ≤1.5 x ULN , INR ≤ 1.5 x ULN , Alanine aminotransferase ( ALT ) , Aspartate aminotransferase ( AST ) , Alkaline phosphatase ( ALP ) ≤2.5 x ULN ( ≤ 5 x ULN participant liver metastasis ) ) . Participants treat anticoagulant , warfarin heparin , allow participate provide prior evidence underlie abnormality parameter exist . 7 . Adequate cardiac function ( Left Ventricular Ejection Fraction ( LVEF ) ≥ 50 % low limit normal ( LLN ) Institution ( whichever low ) . Cardiac function assess within 3 month prior randomisation , completion anthracycline contain chemotherapy . 8 . Willing able comply study requirement , include treatment , time and/or nature require assessment followup . 9 . Study treatment plan able start within 7 day randomisation . 10 . Signed , write informed consent . 1 . Known allergy investigational product drug class excipients regorafenib 2 . Poorly control hypertension ( systolic blood pressure &gt; 140mmHg diastolic pressure &gt; 90mmHg despite optimal medical management ) . 3 . Participants know uncontrolled malabsorption syndromes 4 . Any prior antiVEGF target therapy use small molecule VEGF TKIs ( e.g . apatinib ) . Prior antiVEGF target monoclonal antibody therapy ( e.g . bevacizumab ramucirumab ) permit . 5 . Treatment previous drug therapy within 4 week prior randomization . This include investigational therapy . 6 . Use biological response modifier , granulocyte colony stimulate factor ( GCSF ) , within 3 week prior randomisation . 7 . Concurrent treatment strong CYP3A4 inhibitor inducer . 8 . Palliative radiotherapy , unless 14 day elapse completion radiation date registration , adverse event result radiation resolve &lt; Grade 2 accord CTCAE V4.03 9 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior randomization 10 . Arterial thrombotic ischaemic event , cerebrovascular accident within 6 month prior randomization . 11 . Venous thrombotic event pulmonary embolism within 3 month prior randomization 12 . Any haemorrhage bleeding event ≥ Grade 3 accord CTCAE v4.03 within 4 week prior randomization . 13 . Nonhealing wound , ulcer , bone fracture . 14 . Interstitial lung disease ongoing sign symptom 15 . Abnormal thyroid function ( TSH outside normal range ) . 16 . Persistent proteinuria ≥ Grade 3 accord CTCAE v4.03 ( Formal testing require initial urine analysis use dipstick positive . A random urine protein : creatinine ratio equivalent great 3.5g protein 24 hour consider ineligible . ) 17 . Uncontrolled metastatic disease central nervous system . To eligible , CNS metastases treat surgery and/or radiotherapy patient receive stable dose steroid least 2 week prior randomization , deterioration neurological symptom time . 18 . History another malignancy within 2 year prior randomization . Participants follow eligible study : 1. curatively treated cervical carcinoma situ , 2. nonmelanomatous carcinoma skin , 3. superficial bladder tumour ( T1a [ Noninvasive tumour ] , Tis [ Carcinoma situ ] ) , 4. treat thyroid papillary cancer 19 . Any significant active infection , include chronic active hepatitis B , hepatitis C , HIV . Testing mandatory unless clinically indicate . Participants know Hepatitis B/C infection allow participate provide evidence viral suppression document patient remain appropriate antiviral therapy . 20 . Serious medical psychiatric condition ( ) might limit ability patient comply protocol . 21 . Pregnancy , lactation , inadequate contraception . Women must postmenopausal infertile , use reliable mean contraception . Women childbearing potential must negative pregnancy test do within 7 day prior randomization . Men must surgically sterilize use barrier method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>Locally recurrent</keyword>
	<keyword>Oesophago-gastric junction</keyword>
	<keyword>Stomach</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Undifferentiated Carcinoma</keyword>
</DOC>